Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU)
NCT01047267 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2012-04-06
Summary
The objective of this study is to determine whether pharmacokinetic parameters of anidulafungin correlate with disease severity and plasma protein levels in critically ill patients.
Conditions
- Invasive Candidiasis
- Critically Ill
Sponsors & Collaborators
-
University Medical Center Groningen
lead OTHER
Principal Investigators
-
JWC Alffenaar, PharmD, PhD · University Medical Center Groningen
-
MJP van Wanrooy, PharmD · University Medical Center Groningen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-06-30
- Primary Completion
- 2011-11-30
- Completion
- 2011-12-31
Countries
- Netherlands
Study Locations
More Related Trials
-
Pharmacokinetics of Isavuconazole in Patients in the Intensive Care Unit
NCT04777058 ·Status: COMPLETED
-
Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
NCT00761267 ·Status: COMPLETED ·Phase: PHASE3
-
Therapeutic Drug Monitoring of Fluconazole in Critically Ill Patients
NCT04252027 ·Status: COMPLETED
-
Pharmacokinetics of Micafungin in Patients Intensive Care Unit
NCT01783379 ·Status: COMPLETED
-
Therapeutic Drug Monitoring of Antifungals in Intensive Care Units
NCT04502771 ·Status: COMPLETED
-
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
NCT00689338 ·Status: COMPLETED ·Phase: PHASE3
-
Anidulafungin PK in Infants and Toddlers
NCT00734500 ·Status: COMPLETED ·Phase: PHASE1
-
Variability of Fluconazole Concentration in Critically Ill Patients
NCT02491151 ·Status: COMPLETED
-
Pharmacokinetics of Micafungin in Patients of Intensive Care Units
NCT02164890 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit
NCT02510053 ·Status: UNKNOWN ·Phase: NA
-
Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom
NCT01202253 ·Status: COMPLETED
-
Negative Beta Glucan in ICU Patients
NCT01734525 ·Status: COMPLETED ·Phase: PHASE4
-
Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU
NCT00048750 ·Status: TERMINATED ·Phase: PHASE3
-
Pharmacokinetic of Posaconazole in Critically Ill Patients
NCT05275179 ·Status: COMPLETED
-
β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients
NCT00672841 ·Status: COMPLETED ·Phase: NA
-
Invasive Candidiasis in Critical Care
NCT06456151 ·Status: RECRUITING
-
Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations
NCT01307930 ·Status: COMPLETED ·Phase: PHASE4
-
De-escalation - Antifungal Treatment Immunocompromised Patients
NCT03774316 ·Status: COMPLETED
-
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
NCT00940017 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation
NCT01666769 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability of Voriconazole
NCT02110316 ·Status: WITHDRAWN ·Phase: PHASE4
-
Pharmacokinetics/Pharmacodynamics (PK/PD) of Fluconazole in Children on Extracorporeal Membrane Oxygenation (ECMO)
NCT01169402 ·Status: COMPLETED ·Phase: PHASE1
-
Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections
NCT06387667 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Kinetics of Serum β-D-glucan During Peritonitis With Candida in Resuscitation
NCT03140748 ·Status: COMPLETED ·Phase: NA
-
Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
NCT00056381 ·Status: COMPLETED ·Phase: PHASE1/PHASE2